• Home
  • Research
  • Research News
  • Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas

Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas

European Journal of Endocrinology, 07/08/2013


Auriemma RS et al. – Cabergoline (CAB) has been found to be associated with increased risk of cardiac valve regurgitation in Parkinson's disease (PD), whereas several retrospective analyses failed to detect a similar relation in hyperprolactinemic patients. The current study aimed at investigating cardiac valve disease before and after 24 and 60 months of continuous treatment with CAB only in patients with hyperprolactinemia. CAB does not increase the risk of significant cardiac valve regurgitation in prolactinomas after the first five years of treatment.

Print

Available Now!

PPRG6-500 Cover
The Pituitary Patient Resource Guide Sixth Edition is now available! Be one of the first to have the most up-to-date information. The Pituitary Patient Resource Guide a one of a kind publication intended as an invaluable source of information not only for patients but also their families, physicians, and all health care providers. It contains information on symptoms, proper testing, how to get a diagnosis, and the treatment options that are available. It also includes Pituitary Network Association's patient resource listings for expert medical care.

Buy Now